Clinical pharmacology of anti-il-17 receptor antibody khk4827 (brodalumab) in Japanese healthy volunteers and subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study

被引：0
|
作者：
Nemoto, O. [1 ]
Nagashima, H. [2 ]
Sayama, K. [3 ]
Kobayashi, H. [4 ]
机构：
[1] Sapporo Skin Clin, Sapporo, Hokkaido, Japan
[2] Yanagibashi Hosp, Yanagibashi Clin Trial Ctr, Tokyo, Japan
[3] Ehime Univ, Grad Sch Med, Dept Dermatol, Matsuyama, Ehime 790, Japan
[4] Med Corp Shinanokai, Shinanozaka Clin, Tokyo, Japan
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P049
引用
收藏
页码：21 / 22
页数：2
相关论文
共 50 条
  • [1] Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: A randomized, dose-escalation, placebo-controlled study
    Osamu, Nemoto
    Hirotaka, Nagashima
    Koji, Sayama
    Kenji, Takazawa
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2014, 75 (03) : 201 - 204
  • [2] Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma
    Busse, William W.
    Holgate, Stephen
    Kerwin, Edward
    Chon, Yun
    Feng, JingYuan
    Lin, Joseph
    Lin, Shao-Lee
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 188 (11) : 1294 - 1302
  • [3] Clinical efficacy and safety of brodalumab (KHK4827), an antiinterleukin-17-receptor a monoclonal antibody, in Japanese patients with moderate to severe plaque psoriasis: An open-label extension (OLE) study (4827-003 study)
    Yoshinori, Umezawa
    Nakagawa, Hidemi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB228 - AB228
  • [4] Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial
    Papp, Kim A.
    Reid, Cathy
    Foley, Peter
    Sinclair, Rod
    Salinger, David H.
    Williams, Gary
    Dong, Hua
    Krueger, James G.
    Russell, Chris B.
    Martin, David A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 (10) : 2466 - 2469
  • [5] A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics
    Hodsman, Peter
    Ashman, Claire
    Cahn, Anthony
    De Boever, Erika
    Locantore, Nicholas
    Serone, Adrian
    Pouliquen, Isabelle
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (01) : 118 - 128
  • [6] Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study
    Tehranchi, Ramin
    Pettersson, Jonas
    Melgaard, Anita E.
    Seitz, Friedeborg
    Valeur, Anders
    Maarbjerg, Stine Just
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2022, 96
  • [7] Clinical efficacy and safety of brodalumab (KHK4827), antiinterleukin-17-receptor a monoclonal antibody, in Japanese patients with pustular psoriasis (generalized) and psoriatic erythroderma: A phase 3, open-label, long-term study (4827-004 study)
    Yamasaki, Kenshi
    Nakagawa, Hidemi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB228 - AB228
  • [8] A randomized, placebo-controlled, dose-escalation, phase 1 study of the safety and pharmacokinetics of amphotericin B inhalation powder in healthy subjects
    Marcantonio, Annette
    Kugler, Alan R.
    Sahner, David
    Mufti, Nina
    Lee, Jonathan D.
    Samford, Lori K.
    Eldon, Michael A.
    BLOOD, 2007, 110 (11) : 324B - 324B
  • [9] Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study
    Nagashima, H.
    Suzuki, M.
    Araki, S.
    Yamabe, T.
    Muto, C.
    OSTEOARTHRITIS AND CARTILAGE, 2011, 19 (12) : 1405 - 1412
  • [10] Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study
    Landen, Jaren W.
    Zhao, Qinying
    Cohen, Sharon
    Borrie, Michael
    Woodward, Michael
    Billing, Clare B., Jr.
    Bales, Kelly
    Alvey, Christine
    McCush, Fred
    Yang, Jerry
    Kupiec, James W.
    Bednar, Martin M.
    CLINICAL NEUROPHARMACOLOGY, 2013, 36 (01) : 14 - 23
12345